Histogen Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-11-04: Form 8-K; Period of report 2015-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-09-23: Form 8-K; Period of report 2015-09-23; Description 8.01 Other Events; Details 8.01.
- 2015-08-05: Form 8-K; Period of report 2015-08-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-06-25: Form 8-K; Period of report 2015-06-25; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-11-04 | 8-K | 2015-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2015, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and nine months ended September 30, 2015. | gff8k_110415.htm |
| 2015-09-23 | 8-K | 2015-09-23 | 8.01 Other Events | 8.01 On September 23, 2015, Conatus Pharmaceuticals Inc. (the “Company”) announced that the Company’s exploratory Phase 2 Portal Hypertension (“PH”) clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor, met the following primary endpoints: a) a clinically meaningful and statistically significant change from baseline in hepatic venous pressure gradient (“HVPG”), a measurement of pressure in the portal vein, in patients with liver cirrhosis and severe portal hypertension (HVPG ≥12 mmHg); and b) a statistically significant change from baseline in cleaved Cytokeratin 18 (“cCK18”), a mechanism-specific biomarker of excessive cell death that contributes to chronic inflammation, in the total evaluable liver cirrhosis patient population. | gff8k_092315.htm |
| 2015-08-05 | 8-K | 2015-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2015, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and six months ended June 30, 2015. | gff8k_080515.htm |
| 2015-06-25 | 8-K | 2015-06-25 | 8.01 Other Events | 8.01 On June 25, 2015, Conatus Pharmaceuticals Inc. (the “Company”) announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the Company’s Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant (“POLT”) recipients. | f8k_062515.htm |
| 2015-06-15 | 8-K | 2015-06-11 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Conatus Pharmaceuticals Inc. (the “Company”) held its annual meeting of stockholders on June 11, 2015. | f8k_061515.htm |
| 2015-06-04 | 8-K | 2015-05-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | f8k_060415.htm |
| 2015-05-07 | 8-K | 2015-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2015, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter ended March 31, 2015. | f8k_050715.htm |
| 2015-04-02 | 8-K | 2015-04-02 | 8.01 Other Events | 8.01 On April 2, 2015, Conatus Pharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated and Roth Capital Partners, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 3,500,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). | d901653d8k.htm |
| 2015-03-26 | 8-K | 2015-03-26 | 8.01 Other Events | 8.01 On March 26, 2015, Conatus Pharmaceuticals Inc. (the “Company”) announced top-line results from the Company’s Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH). | f8k_032615.htm |
| 2015-03-11 | 8-K | 2015-03-11 | 2.02 Results of Operations and Financial Condition | 2.02 On March 11, 2015, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2014. | f8k_031115.htm |
| 2015-03-05 | 8-K | 2015-03-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 2, 2015, Gary C. Burgess, M.B., Ch.B. M.Med., tendered his resignation as Senior Vice President, Clinical Research and Chief Medical Officer of Conatus Pharmaceuticals Inc., effective April 2, 2015. | f8k_030515.htm |
| 2015-02-25 | 8-K | 2015-02-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 23, 2015, the Compensation Committee of the Board of Directors (the “Board”) of Conatus Pharmaceuticals Inc. (the “Company”) established the base salaries to be paid to the executive officers listed below, effective January 1, 2015, set target cash bonuses for the 2015 fiscal year for each of the executive officers listed below and approved cash bonus payments for the 2014 fiscal year to be paid to each of the executive officers listed below. | f8k_022515.htm |
| 2015-01-08 | 8-K | 2015-01-08 | 8.01 Other Events | 8.01 On January 8, 2015, Conatus Pharmaceuticals Inc. (the “Company”) announced aggregate top-line results from three pharmacokinetic and pharmacodynamic clinical trials in organ-impaired patients, which include a Phase 2 clinical trial in patients with acute-on-chronic liver failure (“ACLF”), a Phase 1 clinical trial in patients with mild, moderate and severe hepatic impairment and a Phase 1 clinical trial in patients with severe renal impairment. | f8k_010815.htm |